Abstract:Although nucleos(t)ide analog (NA) monotherapy is effective in hepatitis B virus suppression and fibrosis regression, serological response rates are not satisfactory. Studies assessing the benefits of combination therapy with NAs and peginterferon alpha (PegIFNα) in patients with chronic hepatitis B (CHB) have produced conflicting results and mainly focused on serological outcomes. Histological changes in response to combination therapy have not been evaluated in real-world practice. This study aimed to evaluate the histological changes in response to NA-PegIFNα combination therapy in CHB patients and to comprehensively compare the efficacy of NA-PegIFNα combination therapy and NA monotherapy. We conducted a retrospective analysis of data from 40 CHB patients who underwent either NA-PegIFNα combination therapy or NA monotherapy. Changes in histology at 48 weeks after treatment initiation were evaluated. Serological characteristics were also analysed and compared between the NA-PegIFNα combination therapy and NA monotherapy groups and between histological responders and nonresponders. Compared to baseline biopsies, both fibrosis staging and necroinflammatory grading scores were significantly lower in the second biopsies examined post-treatment in both groups. Nearly all patients experienced a reduction in inflammation (87.5% in both groups), but there was a subgroup of patients who exhibited either no significant improvement or fibrosis progression (33.3% and 31.2% in the NA monotherapy and NA-PegIFNα combination therapy groups, respectively). Nearly, all patients achieved ALT normalization and sustained virological response (SVR) after 48 weeks of antiviral treatment. Approximately one-third of individuals (36.8% and 30% in the two groups, respectively) achieved HBeAg loss at 48 weeks after treatment initiation. Although there were no significant differences in overall rates of histological, biochemical, virological and serological responses between the two groups, an earlier virological response and a higher cumulative SVR rate over time were observed during long-term follow-up in patients treated with NA-PegIFNα combination therapy (P = 0.0129). Trends of more rapid HBeAg loss and a higher cumulative HBeAg loss rate throughout long-term follow-up were also observed but were not statistically significant. The ALT normalization rates at 24 and 48 weeks after treatment initiation were associated with the histological response. Significant regression of fibrosis and resolution of necroinflammation were induced with either NA-PegIFNα combination therapy or NA monotherapy. Significant biochemical, virological and serological responses were observed in both groups, and the response rates at 48 weeks were similar in the two groups. Over time during long-term follow-up, the virological and serological responses were faster and superior following the combination regimen.

Long-term Clinical Benefit of Peg-IFNα and NAs Sequential Anti-Viral Therapy on HBV Related HCC.

Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.

Histological Responses of Peginterferon Alpha Add-on Therapy in Patients with Chronic Hepatitis B with Advanced Liver Fibrosis after Long-Term Nucleos(t)ide Analog Treatment

Increase of Hepatitis B Surface Antigen Loss Rate in Hepatitis B E Antigen Positive Chronic Hepatitis B Patients Treated with Nucleos (t) Ide Analogs and Pegylated Interferon Alfa-2A Sequential Therapy

A Potential Functional Cure In Chinese Hbeag-Negative Chronic Hepatitis B Patients Treated With Peg-Interferon Alpha-2a

Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Responding to Peg-IFN Treatment

Sustained Serological and Complete Responses in HBeAg-positive Patients Treated with Peginterferon Alfa-2B: a 6-Year Long-Term Follow-Up of a Multicenter, Randomized, Controlled Trial in China

Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B

Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis

Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B

Long-term effect of nucleoside(tide) analogues and interferon treatment on hepatocellular carcinoma occurrence and death in chronic HBV-infected patients

Interferon-based Treatment is Superior to Nucleos(t)ide Analog in Reducing HBV-related Hepatocellular Carcinoma for Chronic Hepatitis B Patients at High Risk

Effects of Antiviral Therapy on Preventing Liver Tumorigenesis and Hepatocellular Carcinoma Recurrence

Randomized Clinical Trial: Nucleos(t)ide Analogues Improved Survival of CHB-related HCC Patients Via Reducing Severity and Progression of Malignancy

Efficacy of Antiviral Therapy with Nucleotide/nucleoside Analogs after Curative Treatment for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: an Updated Meta-Analysis.

Preliminary study on the efficacy of sequential therapy with nucleotide analogues followed by interferon alpha in chronic hepatitis B patients with low HBsAg level

The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk

Efficacy of Peginterferon alfa-2b in Nucleoside Analogue Experienced Patients with Negative HBeAg and Low HBsAg: A Non-Randomized Clinical Trial

Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase